Teva Acquires Emalex Biosciences

Teva Pharmaceuticals, a global pharmaceutical company, reported strong first quarter results, with its innovative drug portfolio driving growth despite a decline in generic drug revenue. The company also announced its first acquisition in a decade, acquiring Emalex Biosciences, a biopharmaceutical company specializing in treatments for nervous system disorders, including Tourette's syndrome and tardive dyskinesia. Teva's CEO highlighted the acquisition as a strategic move to address unmet medical needs and expand its portfolio, leveraging the company's strengths in marketing and patient access.